2015 American Transplant Congress
De Novo Once-Daily Tacrolimus in Liver Transplantation: Long-Term Outcomes of a Single Center Cohort of 150 Patients
Purpose: To describe the long-term safety and efficacy profile of de novo once-daily tacrolimus (Tac QD) in orthotopic liver transplantation (OLT)Patients and methods: A retrospective…2015 American Transplant Congress
Tacrolimus Trough Concentrations Increase in Intestinal Transplant Recipients During Episodes of Acute Cellular Rejection
Introduction: Acute cellular rejection (ACR) in small bowel transplant recipients is expected to increase intestinal permeability and to reduce intestinal CYP3A/p-glycoprotein activity. These changes may…2015 American Transplant Congress
Comparison of Renal Outcomes for Liver Transplant Recipients With Pretransplant Renal Dysfunction Receiving Sirolimus Or Tacrolimus With Rabbit Antithymocyte Globulin Induction
Published data are limited describing renal outcomes in orthotopic liver transplant (OLT) recipients prescribed de novo sirolimus (SRL) maintenance immunosuppression and rabbit antithymocyte globulin (rATG).…2015 American Transplant Congress
Effects of Immunosuppressives On Porcine Renal Microvascular Endothelial Cell–Activated Human T Cell Proliferation: A Cellular Model of Kidney Xenotransplantation In Vitro
Surgery, Indiana University School of Medicine, Indianapolis, IN.
Background: The creation of genetically-modified pigs has brought us closer than ever to clinical xenotransplantation. However, the optimal immunosuppressive doses still need to be established…2015 American Transplant Congress
Single Cell Phospho-Protein Analysis Demonstrates That Immunosuppressive Drugs Inhibit MAPK and mTOR Signaling Molecules in Primary Monocytes After Transplantation
Nephrology and Transplantation, Dept. of Internal Medicine, Erasmus MC, Rotterdam, Netherlands.
Monocytes have been identified as key players driving rejection processes. It is therefore surprising that there are almost no data available about the impact of…2015 American Transplant Congress
Biomarker for Calcineurin Inhibitors Nephrotoxicity in Solid Organ Transplantation: Validation of a Urine Gene Expression Panel
Background: We previously described a gene expression signature as biomarker of calcineurin inhibitor nephrotoxicity (CNIT) post renal transplantation. Herein, we aimed to validate the same…2015 American Transplant Congress
Phenotypic Personalized Medicine: Mechanism-Independent Convergence Into Target Serum Tacrolimus Levels for Optimized Liver Transplant Immunosuppression
PURPOSE:Immunosuppressive drugs such as tacrolimus have narrow therapeutic ranges and their dosing variability necessitates intensive drug monitoring. This study aimed to use Feedback System Control…2015 American Transplant Congress
Plasma 4β-Hydroxycholesterol Measurement as a Potential Biomarker for CYP3A5 Activity in Informing Tacrolimus Dosing
Background—Recently, 4β-hydroxycholesterol (4β-OHC) has been shown to be an endogenous marker of P450 3A activity in clinical practice (Diczfalusy et al, 2011). 4β-OHC concentration increases…2015 American Transplant Congress
Influence of CYP3A5 and ABCB1 Genotypes on Pharmacokinetics of Immediate and Prolonged Release Tacrolimus Preparations
Background. Tacrolimus is available in two formulations, immediate-release, (Prograf®) and prolonged -release formulation of tacrolimus (Advagraf®). Tacrolimus has a narrow therapeutic index with wide variation…2015 American Transplant Congress
Increasing Tacrolimus Exposure to Minumize Chronic Rejection: How Can We Do It? What Are the Risks?
Background: Recent studies suggest that increased tacrolimus (TAC) exposure may help prevent production of donor specific HLA antibodies (DSAs) that mediate chronic rejection of renal…
American Transplant Congress abstracts